Reversible Tumorigenesis Induced by Deficiency of Vasodilator-Stimulated Phosphoprotein

REFERENCES

• Ahern-Djamali, S. M., A. R. Comer, C. Bachmann, A. S. Kastenmeier, S. K. Reddy, M. C. Beckerle, U. Walter, and J. Hoffmann 1998. Mutations in Drosophila enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 domains. Mol. Biol. Cell 9:2157–2171.
   PubMedGoogle Scholar
• Aszodi, A., A. Pfeifer, M. Ahmad, M. Glauner, X. H. Zhou, L. Ny, K. E. Andersson, B. Kehrel, S. Offermanns, and J. Fassler 1999. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18:37–48.
   PubMed Web of Science ®Google Scholar
• Beckerle, M. C. 1997. Zyxin: zinc fingers at sites of cell adhesion. Bioessays 19:949–957.
   PubMedGoogle Scholar
• Belkin, A. M., and J. Koteliansky 1987. Interaction of iodinated vinculin, metavinculin and α-actinin with cytoskeletal proteins. FEBS Lett. 220:291–294.
   PubMed Web of Science ®Google Scholar
• Bello, M. J., P. E. Leone, P. Nebreda, M. E. Kusak, J. M. Decampos, J. Vaquero, J. L. Sarasa, A. Pestana, and J. Rey 1995. Molecular abnormalities of chromosome 19 in malignant gliomas: preferential involvement of the 19q13.2-19q13.4 region. Int. J. Oncol. 6:655–658.
   PubMedGoogle Scholar
• Ben-Ze’ev, A. 1985. The cytoskeleton in cancer cells. Biochim. Biophys. Acta 780:197–212.
   PubMedGoogle Scholar
• Bicher, A., K. Ault, A. Kimmelman, D. Gershenson, E. Reed, and J. Liang 1997. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecol. Oncol. 66:36–40.
   PubMedGoogle Scholar
• Bookstein, R., J. Y. Shew, P. L. Chen, P. Scully, and J. Lee 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715.
   PubMed Web of Science ®Google Scholar
• Brindle, N. P., M. R. Holt, J. E. Davies, L. J. Price, and J. Critchley 1996. The focal-adhesion vasodilator-stimulated phosphoprotein (VASP) binds to the proline-rich domain in vinculin. Biochem. J. 318:753–757.
   PubMed Web of Science ®Google Scholar
• Butt, E., K. Abel, M. Krieger, D. Palm, V. Hoppe, J. Hoppe, and J. Walter 1994. cAMP- and cCMP-dependent protein kinase phophorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J. Biol. Chem. 269:14509–14517.
   PubMed Web of Science ®Google Scholar
• Cartwright, C. A., W. Eckhart, S. Simon, and J. Kaplan 1987. Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell 49:83–91.
   PubMed Web of Science ®Google Scholar
• Chakraborty, T., F. Ebel, E. Domann, K. Niebuhr, B. Gerstel, S. Pistor, C. J. Temm-Grove, B. M. Jockusch, M. Reinhard, U. Walter, and J. Wehland 1995. A novel focal adhesion factor directly linking the intracellularly motile Listeria monocytogenes and Listeria ivanovii to the actin-based cytoskeleton of mammalian cells. EMBO J. 14:1314–1321.
   PubMedGoogle Scholar
• Cifone, M. A., and J. Fidler 1980. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc. Natl. Acad. Sci. USA 77:1039–1043.
   PubMed Web of Science ®Google Scholar
• Crawford, A. W., and J. Beckerle 1991. Purification and characterization of zyxin, and 82,000-dalton component of adherens junctions. J. Biol. Chem. 266:5847–5853.
   PubMedGoogle Scholar
• Cui, W., D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain, and J. Akhurst 1996. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531–542.
   PubMed Web of Science ®Google Scholar
• Dosaka-Akita, H., F. Hommura, H. Fujita, I. Kinoshita, M. Nishi, T. Morikawa, H. Katoh, Y. Kawakami, and J. Kuzumaki 1998. Frequent loss of gelsolin expression in no-small cell lung cancers of heavy smokers. Cancer Res. 15:322–327.
   Google Scholar
• Fearon, E., K. Cho, J. Nigro, S. Kern, J. Simon, J. Ruppert, S. Hamilton, A. Preisinger, G. Thomas, K. Kinsler, and J. Vogelstein 1990. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49–56.
   PubMed Web of Science ®Google Scholar
• Feinberg, A. P., and J. Vogelstein 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6–13.
   PubMed Web of Science ®Google Scholar
• Fernadez, J. L. R., B. Geiger, D. Salomon, M. Z. Sabanay, and J. Ben-Ze’ev 1992. Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J. Cell Biol. 119:427–438.
   PubMedGoogle Scholar
• Fidler, I. J., and J. Hart 1982. Biological diversity in metastatic neoplasms: origins and implications. Science 217:998–1003.
   PubMed Web of Science ®Google Scholar
• Freedman, V. H., and J. Shin 1974. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3:355–359.
   PubMed Web of Science ®Google Scholar
• Gluck, U., D. J. Kwiatkowski, and J. Ben-Ze’ev 1993. Suppression of tumorigenicity in simian virus 40-transformed 3T3 cells transfected with α-actinin cDNA. Proc. Natl. Acad. Sci. USA 90:383–387.
   PubMed Web of Science ®Google Scholar
• Gualberto, A., K. Aldape, K. Kozakiewicz, and J. Tlsty 1998. An oncogenic form of p53 confers a dominant, gain of function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95:5166–5171.
   PubMed Web of Science ®Google Scholar
• Haber, D., and J. Harlow 1997. Tumour-suppressor genes: evolving definitions in the genomic age. Nat. Genet. 16:320–322.
   PubMed Web of Science ®Google Scholar
• Haffner, C., T. Jarchau, M. Reinhard, J. Hoppe, S. M. Lohmann, and J. Walter 1995. Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP. EMBO J. 14:19–27.
   PubMedGoogle Scholar
• Halbrugge, M., and J. Walter 1989. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur. J. Biochem. 185:41–50.
   PubMedGoogle Scholar
• Halbrugge, M., C. Friedrich, M. Eigenthaler, P. Schanzenbacher, and J. Walter 1990. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J. Biol. Chem. 265:3088–3093.
   PubMed Web of Science ®Google Scholar
• Hartwell, L. H., T. A. Weiner, L. Kadyk, and J. Garvik 1994. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harbor Symp. Quant. Biol. 49:259–263.
   Google Scholar
• Holt, M. R., D. R. Critchley, and J. Brindle 1998. The focal adhesion phosphoprotein, VASP. Int. J. Biochem. Cell Biol. 30:307–311.
   PubMedGoogle Scholar
• Huang, H. J., J. K. Yee, J. Y. Shew, P. L. Chen, R. Bookstein, T. Friedmann, E. Y. Lee, and J. Lee 1988. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566.
   PubMed Web of Science ®Google Scholar
• Huttelmaier, S., O. Mayboroda, B. Harbeck, T. Jarchau, B. M. Jockusch, and J. Rudiger 1998. The interaction of the cell-contact proteins VASP and vinculin is regulated by phosphatidylinositol-4,5-bisphosphate. Curr. Biol. 8:479–488.
   PubMedGoogle Scholar
• Keely, P., L. Parise, and J. Juliano 1998. Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. 8:101–106.
   PubMed Web of Science ®Google Scholar
• Kimura, Y., H. Koga, N. Araki, N. Mugita, N. Fujita, H. Takeshima, T. Nishi, T. Yamashima, T. Saido, T. Yamasaki, K. Moritake, H. Saya, and J. Nakao 1998. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat. Med. 4:915–922.
   PubMed Web of Science ®Google Scholar
• Kinzler, K. W., and J. Vogelstein 1997. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 386:761–763.
   PubMed Web of Science ®Google Scholar
• Klein, G. 1987. The approaching era of the tumor suppressor genes. Science 238:1539–1545.
   PubMed Web of Science ®Google Scholar
• Knudson, A. J. 1993. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 90:10914–10921.
   PubMed Web of Science ®Google Scholar
• Levine, A. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Levine, A. J., J. Momand, and J. Finlay 1991. The p53 tumor suppressor gene. Nature 351:453–456.
   PubMed Web of Science ®Google Scholar
• Li, L., J. E. Price, D. Fan, R. D. Zhang, C. D. Bucana, and J. Fidler 1989. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J. Natl. Cancer Inst. 81:1406–1412.
   PubMed Web of Science ®Google Scholar
• Li, L., and J. Cohen 1996. tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319–329.
   PubMed Web of Science ®Google Scholar
• Lo, S. H., E. Weisberg, and J. Chen 1994. Tensin: a potential link between the cytoskeleton and signal transduction. Bioessays 16:817–823.
   PubMed Web of Science ®Google Scholar
• Lupton, S. D., L. L. Brunton, V. A. Kalberg, and J. Overell 1991. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11:3374–3378.
   PubMed Web of Science ®Google Scholar
• Machesky, L. M., and J. Pollard 1993. Profilin as a potential mediator of membrane-cytoskeleton communication. Trends Cell Biol. 3:381–385.
   PubMedGoogle Scholar
• Martin, M., C. Andeoli, A. Sahuquet, P. Montcourrier, M. Algrain, and J. Mangeat 1995. Ezrin NH2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J. Cell Biol. 128:1081–1093.
   PubMedGoogle Scholar
• Matthew, L. F., E. Randel, K. E. Gurley, J. M. Roberts, and J. Kemp 1998. The murine gene p27KIP1 is haplo-insufficient for tumour suppression. Nature 396:177–180.
   PubMedGoogle Scholar
• Narayanan, R., K. G. Lawlor, R. Q. Schaapveld, K. R. Cho, B. Vogelstein, P. Bui-Vinh Tran, M. P. Osborne, and J. Telang 1992. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7:553–561.
   PubMed Web of Science ®Google Scholar
• Pejovic, T. 1995. Genetic changes in ovarian cancer. Ann. Med. 27:73–78.
   PubMed Web of Science ®Google Scholar
• Prasad, G. L., R. A. Fuldner, and J. Cooper 1993. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc. Natl. Acad. Sci. USA 90:7039–7043.
   PubMed Web of Science ®Google Scholar
• Raz, A., and J. Geiger 1982. Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities. Cancer Res. 42:5183–5190.
   PubMedGoogle Scholar
• Reinhard, M., M. Halbrugge, U. Scheer, C. Wiegand, B. M. Jockusch, and J. Walter 1992. The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. EMBO J. 11:2063–2070.
   PubMed Web of Science ®Google Scholar
• Reinhard, M., K. Giehl, K. Abel, C. Haffner, T. Jarchau, V. Hoppe, B. Jockusch, and J. Walter 1995. The proline-rich focal adhesion and microfilament protein VASP is a ligand for profilins. EMBO J. 14:1583–1589.
   PubMed Web of Science ®Google Scholar
• Reinhard, M., K. Jouvenal, D. Tripier, and J. Walter 1995. Identification, purification, and characterization of a zyxin-related protein that binds the focal adhesion and microfilament protein VASP (vasodilator-stimulated phophoprotein). Proc. Natl. Acad. Sci. USA 74:5463–5467.
   Google Scholar
• Ritland, S. R., V. Ganju, and J. Jenkins 1995. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12:277–282.
   PubMedGoogle Scholar
• Rosenberg, J. E., D. K. Lisle, J. A. Burwick, K. Ueki, A. vonDeimling, H. W. Mohrenweiser, and J. Louis 1996. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483–2485.
   PubMedGoogle Scholar
• Rubio, M. P., K. M. Correa, K. Ueki, H. W. Mohrenweiser, J. F. Gusella, A. vonDeimling, and J. Louis 1994. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res. 54:4760–4763.
   PubMed Web of Science ®Google Scholar
• Sadler, I., A. W. Crawford, J. W. Michelsen, and J. Beckerle 1992. Zyxin and cCRP: two interactive LIM domain proteins associated with the cytoskeleton. J. Cell Biol. 119:1573–1587.
   PubMed Web of Science ®Google Scholar
• Schwartz, M. A. 1997. Integrins, oncogenes, and anchorage independence. J. Cell Biol. 39:575–578.
   Google Scholar
• Scoles, D. R., D. P. Huynh, P. A. Morcos, E. R. Coulsell, N. G. G. Robinson, F. Tamanoi, and J. Pilst 1998. Neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin. Nat. Genet. 18:354–359.
   PubMed Web of Science ®Google Scholar
• Shaw, R. J., A. I. McClatchey, and J. Jacks 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, Merlin, by adhesion and growth arrest stimuli. J. Biol. Chem. 273:7757–7764.
   PubMedGoogle Scholar
• Suetsugu, S., H. Miki, and J. Takenawa 1998. The essential role of profilin in the assembly of actin for microspike formation. EMBO J. 17:6516–6526.
   PubMedGoogle Scholar
• Takeuchi, K., N. Sato, H. Kasahara, N. Funayama, A. Nagafuchi, S. Yonemura, S. Tsukita, and J. Tsukita 1994. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J. Cell Biol. 125:1371–1384.
   PubMed Web of Science ®Google Scholar
• Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Jetterio, and J. Wakefield 1998. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:802–807.
   PubMed Web of Science ®Google Scholar
• Turner, C. E., J. R. Glenney, and J. Burridge 1990. Paxillin: a new vinculin binding protein present in focal adhesions. J. Cell Biol. 111:1059–1068.
   PubMed Web of Science ®Google Scholar
• Venkatachalam, S., Y. Shi, S. N. Jones, H. Vogel, A. Bradley, D. Pinkeland, and J. Donehower 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:4657–4667.
   PubMed Web of Science ®Google Scholar
• Waldmann, R., M. Nieberding, and J. Walter 1987. Vasodilator-stimulated protein phophorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur. J. Biochem. 167:441–448.
   PubMedGoogle Scholar
• Weiss, E. E., M. Kroemker, A. Rudiger, B. M. Jockusch, and J. Rudiger 1998. Vinculin is part of the cadherin-catenin junctional complex: complex formation between α-catenin and vinculin. J. Cell Biol. 141:755–764.
   PubMedGoogle Scholar
• White, R. L. 1998. Tumor suppressing pathways. Cell 92:591–592.
   PubMedGoogle Scholar
• Wilkins, J. A., M. A. Risinger, and J. Lin 1986. Studies of proteins that co-purify with smooth muscle vinculin: identification of immunologically related species in focal adhesions of nonmuscle and Z-lines of muscle cells. J. Cell Biol. 102:1483–1494.
   Google Scholar
• Xie, W., L. Li, and J. Cohen 1998. Cell cycle-dependent subcellular localization of the tsg101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl. Acad. Sci. USA 95:1595–1600.
   PubMed Web of Science ®Google Scholar
• Zimmer, M., T. Fink, L. Fiselore, W. Hauser, K. Scherer, P. Lichter, and J. Walter 1996. Cloning of the VASP (vasodilator-stimulated phosphoprotein) genes in human and mouse: structure, sequence, and chromosomal localization. Genomics 36:227–233.
   PubMedGoogle Scholar